Posterior microphthalmia and nanophthalmia in Tunisia caused by a founder c.1059_1066insC mutation of the PRSS56 gene
2013 (English)In: Gene, ISSN 0378-1119, E-ISSN 1879-0038, Vol. 528, no 2, 288-294 p.Article in journal (Refereed) Published
Congenital microphthalmia (CMIC) is a common developmental ocular disorder characterized by a small, and sometimes malformed, eye. Posterior microphthalmia (PM) and nanophthalmia are two rare subtypes of isolated CMIC characterized by extreme hyperopia due to short axial length and elevated lens/eye volume ratio. While nanophthalmia is associated with a reduced size in both anterior and posterior segments, PM involves a normal-size anterior chamber but a small posterior segment. less thanbrgreater than less thanbrgreater thanSeveral genes encoding transcription and non-transcription regulators have been identified in different forms of CMIC. MFRP gene mutations have, for instance, been associated with nanophthalmia, and mutations in the recently identified PRSS56 gene have been linked to PM. So far, these two forms of CMIC have been associated with 9 mutations in PRSS56. Of particular interest, a c.1059_1066insC mutation has recently been reported in four Tunisian families with isolated PM and one Tunisian family with nanophthalmia. Here, we performed a genome-wide scan using a high density single nucleotide polymorphism (SNP) array 50 K in a large consanguineous Tunisian family (PM7) affected with PM and identified the same causative disease mutation. A total of 24 polymorphic markers spanning the PRSS56 gene in 6 families originating from different regions of Tunisia were analyzed to investigate the origin of the c.1059_1066insC mutation and to determine whether it arose in a common ancestor. A highly significant disease-associated haplotype, spanning across the 146 kb of the 2q37.1 chromosome, was conserved in those families, suggesting that c.1059_1066insC arose from a common founder. The age of the mutation in this haplotype was estimated to be around 1850 years. The identification of such founder effects may greatly simplify diagnostic genetic screening and lead to better prognostic counseling.
Place, publisher, year, edition, pages
Elsevier , 2013. Vol. 528, no 2, 288-294 p.
Founder effect, Microarray, Microphthalmia, Nanophthalmia, PRSS56, Tunisia
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-99393DOI: 10.1016/j.gene.2013.06.045ISI: 000324565600030OAI: oai:DiVA.org:liu-99393DiVA: diva2:656931
Funding Agencies|Tunisian Ministry of Higher Education, Scientific Research and Technology||Tunisian Ministry of Women||MENA Project||VR/SIDA|348-2005-6336|2013-10-172013-10-172013-10-17